1 Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. A Mocroft, JD Lundgren, M Ross, CA Fux P Reiss, O Moranne, P Morlat, A d'Arminio Monforte, O Kirk, L Ryom, on behalf of The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D)
Study.
Lancet HIV. 2016 ;3(1):e23-32. abstract
2 Antiretroviral Therapy in Early HIV Infection. J Lundgren, AG Babiker, JD Neaton.
The New England journal of medicine. 2016, 374:393-394. Article
3 Antiretroviral drugs and risk of chronic ALT elevation in HIV-infected persons without viral hepatitis coinfection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study H Kovari, CA Sabin, B Ledergerber, L Ryom, P Reiss, M Law, C Pradier, F Dabis, A d’Arminio Monforte, C Smith, S de Wit, O Kirk, JD Lundgren, R Weber , on behalf of the D:A:D Study group.
Open Forum Infectious Diseases. 2016;3(1). Abstract
4 Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. L Ryom, JD Lundgren, S De Wit, H Kovari, P Reiss, M Law, W El-Sadr, A D’Arminio Monforte, Amanda Mocroft, C Smith, E Fontas, F Dabis, A Phillips and C Sabin for the D:A:D Study Group.
AIDS. 2016;30(11):1731-43. Abstract
5 Predictive value of prostate specific antigen in a European HIV-positive cohort: Does one size fit all? Leah Shepherd, Álvaro H. Borges, Lene Ravn, Richard Harvey, Mark Bower, Andrew Grulich, Michael Silverberg, Gitte Kronborg, Massimo Galli, Ole Kirk, Jens Lundgren, Amanda Mocroft on behalf of EuroSIDA in EuroCoord.
Antiviretroviral Therapy. 2016;21(6):529-534. abstract
6 An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. N. Friis-Møller, L. Ryom, C. Smith, R. Weber, P. Reiss, F. Dabis, S. De Wit, A. d'Arminio Monforte, O. Kirk, E. Fontas, C. Sabin, A. Phillips, J.D. Lundgren, M. Law
European Journal of Preventive Cardiology. 2016;23(2):214-23. abstract
7 Tuberculosis-related mortality in people living with HIV In Europe and Latin America: an international cohort study. Daria Podlekareva, Anne Marie W. Efsen, Anna Schultze, Frank Post,, Alena M. Skrahina, Alexander Panteleev, Hansjakob Furrer, Robert F. Miller, Marcelo H. Losso, Javier Toibaro, Jose M. Miro, Anna Vassilenko, Enrico Girardi, Mathias Bruyans, Niels Obel, Jens D. Lundgren, Amanda Mocroft, Ole kirk on behalf of the TB:HIV study group in EuroCoord.
Lancet HIV. 2016;3(3):e120-31. abstract
8 A method to estimate the size and characteristicsof HIV-positive populations using an individual-based stochastic simulation model. F Nakagawa, A van Sighem, R Thiebaut, C Smith, O Ratmann, V Cambiano, J Albert, A Amato-Gauci, D Bezemer, C Campbell, D Commenges, M Donoghoe, D Ford, R Kouyos, R Lodwick, J Lundgren, N Pantazis, A Pharris, C Quinten, C Thorne, G Touloumi, V Delpech , A Phillips; SSOPHIE project working group in EuroCoord.
Epidemiology. 2016;27(2):247-56. Abstract
9 Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals? DC Boettiger, CA Sabin, A Grulich, L Ryom, F Bonnet, P Reiss, A d’ArminioMonforte, O Kirk, A Phillips, M Bower, G Fätkenheuer, JD Lundgren, M Law on behalf of the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group
AIDS. 2016 ;30(10):1629-37. Abstract
10 Infection-related and -unrelated malignancies, HIV and the aging population. Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A, on behalf of EuroSIDA in EuroCoord.
HIV Medicine. 2016 ;17(8):590-600. abstract
11 Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with human immunodeficiency virus (HIV)? A cohort collaboration. CA Sabin; P Reiss; L Ryom; AN Phillips, PhD; R Weber; M Law; E Fontas; A Mocroft; S de Wit; C Smith; F Dabis; A d'Arminio Monforte; W El-Sadr; JD Lundgren for the DAD Study Group.
BMC Medicine. 2016;14(1):61. Abstract
12 Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. CI Hatleberg, L Ryom, W El-Sadr, C Smith, R Weber, P Reiss, E Fontas, F Dabis, M Law, A d’Arminio Monforte, Stephane De Wit, A Mocroft, A Phillips, J D. Lundgren and C Sabin for the D:A:D Study Group
AIDS. 2016;30(10):1583-96. Abstract
13 Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. Amit C Achhra; Amanda Mocroft; Peter Reiss; Caroline Sabin; Lene Ryom; Stephane de Wit; Colette J Smith; Antonella d´arminio Monforte; Andrew Phillips; Rainer Weber; Jens Lundgren; Matthew G Law; The D:A:D Study Group.
HIV Medicine. 2016;17(4):255-68.. abstract
14 IL-6 is a stronger predictor of clinical events than hsCRP or D-dimer during HIV infection. AH Borges,JL O'Connor, AN Phillips, JD Neaton, B Grund, J Neuhaus, MJ Vjecha, A Calmy, KK Koelsch, JD Lundgren; INSIGHT SMART ESPRIT Study Groups.
Journal of Infectious Diseases. 2016 ;214(3):408-16. Abstract
15 Identifying key drivers of the impact of an HIV cure intervention in sub-Saharan Africa. A Phillips A, Cambiano, P Revill , F Nakagawa, J Lundgren, L Bansi-Matharu, T Mabugu, M Sculpher, G Garnett, S Staprans, S Becker, J Murungu, SR Lewin, SG Deeks, T Hallett T.
Journal of Infectious Dieases. 2016;214(1):73-9. Abstract
16 Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. L Ryom, C Boesecke,V Gisler,C Manzardo, JK Rockstroh, M Puoti, H Furrer, JM Miro, JM Gatell, A Pozniak, G Behrens, M Battegay, JD Lundgren, EACS Governing Board.
HIV Medicine. 2016;17(2):83-8. abstract
17 Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy, AJ. Rodger V Cambiano, T Bruun, P Vernazza, S Collins; J van Lunzen, GM Corbelli; V Estrada, AM Geretti, A Beloukas, D Asboe, P Viciana, F Gutiérrez, B Clotet, C Pradier, J Gerstoft, R Weber, K Westling, G Wandeler, JM. Prins, A Rieger, M Stoeckle, T Kümmerle, T Bini, A Ammassari, R Gilson, I Krznaric,M Ristola, R Zangerle, P Handberg, A Antela, S Allan, A N. Phillips, J Lundgren, for the PARTNER Study Group
JAMA. 2016;316(2):171-181. Abstract
18 Associations between HIV-RNA-based indicators and virological and clinical outcomes. K Laut, L Shepherd, C Pedersen, JK Rockstroh, H Sambatakou, D Paduta, R Matulionyte, T Smiatacz, F Mulcahy, JD Lundgren, A Mocroft, O Kirk, on behalf of EuroSIDA in EuroCoord.
AIDS 2016;30(12):1961-72. abstract
19 Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey. JV Lazarus, K Laut, K Safreed-Harmon, L Peters, M Johnson, G Fätkenheuer, I Khromova, L Vandekerckhove, K Maciejewska, R Radoi, AL Ridolfo, A Mocroft, on behalf of EuroSIDA in EuroCoord.
BMC Infectious Diseases 2016 16:335. article
20 Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-positive Adults on Suppressive Antiretroviral Therapy. B Grund, JV Baker, SG Deeks, J Wolfson, D Wentworth, A Cozzi-Lepri, CJ Cohen, A Phillips, JD Lundgren, JD Neaton. INSIGHT SMART/ESPRIT/SILCAAT Study Group.
PLoS One. 2016 12;11(5) abstract
21 Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. L Ryom, JD Lundgren, M Ross, O Kirk, M Law, P Morlat, C Smit, E Fontas, CA Fux, CI Hatleberg, S de Wit, CA Sabin and A Mocroft for the D:A:D Study Group
Journal of Infectious Diseases. 2016;214(8):1212-20. abstract
22 Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. Gjærde LI, Shepherd L Jablonowska E, Lazzarin A, Rougemont M, Darling K, Battegay M, Braun D, Martel-Laferriere V, Lundgren JD, Rockstroh JK, Gill J, Rauch A, Mocroft A, Klein MB, Peters L.
Clininal Infectious Diseases. 2016 ;63(6):821-9. abstract
23 Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: a prospective cohort study JM Llibre, A Cozzi-Lepri, C Pedersen, M Ristola, M Losso, A Mocroft, V Mitsura, K Falconer, F Maltez, M Beniowski, V Vullo, G Hassoun, E Kuzovatova, J Szlavik, A Kuznetsova, H-J Stellbrink, C Duvivier, S Edwards, K Laut, R Paredes for the EuroSIDA Study Group.
Medicine: Volume 95(40), 2016, p e5020. article abstract
24 Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012. A Mozalevskis, I Eramova, K Safreed-Harmon, JV Lazarus.
Eurosurveillance 2016; 21(22). Abstract
25 Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. DA Kamara, CA Sabin, L Ryom, P Reiss, M Rickenbach, CJ Smith, A Phillips, A Mocroft, S De Wit, M Law, A d’Arminio Monforte, F Dabis, C Pradier, JD Lundgren.
Antiviretroviral Therapy. 2016;21(6):495-506. abstract
26 Non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based regimens for initial treatment of HIV infection: a systematicreview and meta-analysis of randomised trials. AH Borges, A Lundh, B Tendal, JA Bartlett, N Clumeck, D Costagliola,ES Daar, P Echeverría, M Gisslén, TB Huedo-Medina, MD Hughes, K Huppler Hullsiek, P Khabo, S Komati, P Kumar, S Lockman, RD MacArthur, F Maggiolo, A Matteelli, JM Miro, S Oka, K Petoumenos, RL Puls, SA Riddler, PE Sax, J Sierra-Madero, C Torti, JD Lundgren.
Clinical Infectious Diseases. 2016. pii: ciw236. Abstract
27 The cardiovascular risk management for people living with HIV in Europe: how well are we doing? M Shahmanesh, A Schultze, F Burns, O Kirk, J Lundgren, C Mussini, C Pedersen, S De Wit, G Kutsyna, A Mocroft on behalf of EuroSIDA in EuroCoord.
AIDS. 2016 ;30(16):2505-2518 abstract
28 Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. KE Darling, A Hachfeld, M Cavassini, O Kirk, H Furrer, G Wandeler.
Swiss Medical Weekly. 2016;146. Abstract
29 Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report.
JD Kowalska, C Oprea,S de Witt, A Pozniak, D Gökengin, M Youle, JD Lundgren, A Horban; ECEE Network Group.
HIV Med. 2016. Abstract
30 The per-protocol effect of immediate vs. deferred ART initiation in the START randomized trial.
S Lodi, S Sharma, JD Lundgren, AN Phillips, SR Cole, R Logan, BK Agan, A Babiker, H Klinker, H Chu, M Law, JD Neaton, MA Hernán; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group.
AIDS. 2016. Abstract
31 Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection. ÁH Borges, J Neuhaus, AG Babiker,K Henry, MK Jain, A Palfreeman, P Mugyenyi, P Domingo, C Hoffmann, TR Read, S Pujari,M Meulbroek, M Johnson, T Wilkin,R Mitsuyasu; INSIGHT START Study Group.
Clinical Infectious Diseases. 2016. pii: ciw621. abstract
32 MELD score measured day 10 after orthotopic liver transplantation predicts death and re-transplantation within the first year. AA Rostved, JD Lundgren, J Hillingsø , L Peters, A Mocroft, A Rasmussen.
Scandinavian Journal of Gastroenterology. 2016, 51 (11), 1360-1366. Abstract
33 European AIDS Clinical Society Standard of Care meeting on HIV and related coninfections: The Rome Statements. C Mussini, A. antinori, S Bhagani, T Branco, M Brostrom, N Dedes, T Bereczky, E Girardi, D Gökengin, A Horban, K Lacombe, JD Lundgren, L Mendao, A Mocroft, C Oprea, K Porter, D Podlekareva, M Battegay, A d'Arminio Monforte. European AIDS Clinical Society.
HIV Medicine. 2016;17(6):445-52. Abstract
34 The clinical utility of PDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. NE Wareham, JD Lundgren, C Da Cuncha-Bang, F Gustafsson, M Iversen, HH Johannesen, A Kjær, A Rasmussen, H Sengeløv, SS Sørensen, BM Fischer.
European Journal Nuclear Medicine Molecular Imaging. 2016. Abstract
35 Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord.
Clinical Infectious Diseases 2016, 63 (9)1245-1253. Abstract
36 Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. A Ronit, J Haissman, DM Kirkegaard-Klitbo, TS Kristensen, AM Lebech, T Benfield, J Gerstoft, H Ullum, L Køber, A Kjær, K Kofoed, J Vestbo, B Nordestgaard, J Lundgren, SD Nielsen.
BMC Infectious Diseases. 2016;16(1):713. Abstract
37 Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. JS Jensen, TS Itenov, KM Thormar, L Hein ,TT Mohr, MH Andersen, J Løken, H Tousi, B Lundgren, HC Boesen, ME Johansen, SR Ostrowski, PI Johansson, J Grarup, J Vestbo, JD Lundgren; Procalcitonin And Survival Study (PASS) Group.
Annals of Intensive Care ;6(1):114. Abstract
38 Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future.
Euro Surveillance. 2016; 21(10). Abstract
39 Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. KM Kunisaki, DE Niewoehner, G Collins, B Aagaard, NB Atako, E Bakowska, A Clarke, GM Corbelli, E Ekong, S Emery, EB Finley, E Florence, RM Infante, CM Kityo, JS Madero, DE Nixon, E Tedaldi, J Vestbo, R Wood, JE Connett; INSIGHT START Pulmonary Substudy Group.
Lancet Respir Med. 2016, 4(12) 980-989. Abstract
40 Pulmonary effects of immediate versus deferred antiretroviral treatment in HIV-positive persons with CD4+ T cell counts >500 cells/mm3: A randomised, controlled trial. Kunisaki K et al.
Lancet Respir Med. 2016 ;4(12):980-989 Abstract
41 Improved quality of life with immediate initiation of antiretroviral therapy in the strategic timing of antiretroviral therapy trial.
AR Lifson, B Grund, EM Gardner, R Kaplan, E Denning, N Engen, CL Carey, F Chen, S Dao, E Florence, J Sanz, S Emery; INSIGHT START Study Group.
AIDS. 2017; 31(7):953-963. Abstract
42 Beyond viral suppression of HIV – the new quality of life frontier. JV Lazarus, K Safreed-Harmon, S E. Barton, D Costagliola, N Dedes, J del Amo Valero, JM Gatell, R Baptista-Leite, L Mendão, K Porter, S Vella and JK Rockstroh
BMC Medicine201614:94 Abstract
43 The Global Fund to Fight AIDS, Tuberculosis and Malaria's investments in harm reduction through the rounds-based funding model (2002-2014).
J Bridge, BM Hunter, E Albers,C Cook, M Guarinieri, JV Lazarus, J MacAllister, S McLean, D Wolfe.
Int J Drug Policy. 2016 ;27:132-7. Abstract
44 Are the testing needs of key European populations affected by hepatitis B and C being addressed? A scoping review of testing studies in Europe. JV Lazarus, I Sperle, EF Duffell, A Spina, JK Rockstroh, L Wiessing.
CMJ, 2016;57:442-56. Abstract
45 HMAP, World Hepatitis Day and the bigger health systems picture. JV Lazarus, K Safreed-Harmon, M Maticic.
HMAP, 2016, 2:4. Abstract
46 Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014). JV Lazarus, A Mozalevskis, K Safreed-Harmon, I Eramova I.
HMAP, 2016, 1:3 Abstract
47 HIV post-test practices: an online survey examining perceived delivery of HIV test results, post-test discussion and referral in healthcare settings across the WHO European Region..
S Bel, J Casabona, N Tsereteli, D Raben, J de Wit.
Sex Health. 2016 Jun;13(3):205-12. Abstract